Zydus Cadila gets USFDA nod for chemo, BP drugs

Zydus Cadila said it has received approval from the US Food and Drug Administration to market chemotherapy drug Temozolomide and blood pressure drug Nadolol.

Temozolomide will be made available in six doses from 5 mg to 250 mg.

It is used in the management of brain tumors.

The market size of Temozolomide is estimated at $100.4 million.

The company also received the final approval from the USFDA to market Nadolol Tablets in three doses.

Nadolol is used in management of hypertension (high blood pressure) and angina pectoris (chest pain).

The sales of Nadolol tablets is estimated at $109.8 million per year.

Both the drugs will be manufactured at the group’s formulations manufacturing facility at the Pharma SEZ, Ahmedabad.

The group now has more than 130 approvals and has so far filed over 300 ANDAS since the commencement of the filing process in FY 2003-04.